Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Last trade$15.21
Day change-$0.22 (-1.43%)
Day range$15.06 – $15.42
Volume28,849
Market cap$86M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$86.41M
Price / earnings
3.22×
Price / book
0.94×
Price / sales
199.1×
EV / sales
-9.87×
EV / EBITDA
0.18×
Profitability
Earnings per share
$4.79
Return on assets
28.05%
Return on equity
29.05%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
28.87×
Quick ratio
28.87×
Cash ratio
27.63×
Cash flow
Price / cash flow
2.79×
Price / free cash flow
2.79×
Free cash flow
$30.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RLYB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$212K
$222K
$212K
$212K
$212K
$38K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$212K
$222K
$212K
$212K
$212K
$38K
Selling, general and administrative
$2.84M
$4.9M
$6.07M
$2.98M
$2.99M
$4.2M
$4.16M
$4.26M
Research and development
$584K
$758K
$2.87M
$3.66M
$4.14M
$6.07M
$5.73M
$7.39M
Total operating expenses
$3.42M
$5.65M
$8.95M
$6.63M
$7.14M
$10.27M
$9.88M
$11.65M
Operating income
-$3.42M
-$5.65M
-$8.73M
-$6.41M
-$6.93M
-$10.06M
-$9.67M
-$11.61M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$2.65M
$44.99M
-$8.28M
-$5.85M
$16.02M
-$9.7M
-$9.44M
-$10.61M
Income taxes
$80K
$1.32M
$0
$0
$0
$0
$0
$0
Net income
-$2.73M
$43.67M
-$8.28M
-$4.98M
$16.02M
-$9.7M
-$9.44M
-$8.81M
Net income attributable to common shareholders
-$2.73M
$43.67M
-$8.28M
-$5.85M
$16.02M
-$9.7M
-$9.44M
-$11.04M
EBITDA
-$3.42M
-$5.65M
-$8.73M
-$6.41M
-$6.89M
-$10.03M
-$9.64M
-$11.58M
Basic earnings per share
-$0.48
$7.66
-$1.46
-$1.03
$2.84
-$1.73
-$1.69
-$1.98
Diluted earnings per share
-$0.48
$7.53
-$1.46
-$1.03
$2.84
-$1.73
-$1.69
-$1.98
Recent news
Company coverage with links to the original publishers.
Halper Sadeh LLC, an investor rights law firm, is investigating QIAGEN N.V., Victory Capital Holdings, Inc., and Rallybio Corporation for potential violations of federal securities laws and breaches of fiduciary duties relating to their proposed mergers and acquisitions. The firm is seeking increased consideration, additional disclosures, and other relief on behalf of shareholders.
Monteverde & Associates PC, a recognized class action securities firm, is investigating four major M&A transactions: Calisa Acquisition Corp.'s merger with Goodvision AI Inc., Talkspace Inc.'s sale to Universal Health Services Inc. at $5.25 per share, Jet.AI Inc.'s merger with flyExclusive Inc., and Rallybio Corporation's merger with Candid Therapeutics Inc. The firm encourages shareholders to seek legal counsel regarding potential concerns with these transactions.
Rallybio Corporation announced a merger agreement with Candid Therapeutics Inc., which has secured over $505 million in financing. The combined company will have approximately $700 million in pro-forma cash to support operations through 2030 and advance T-cell engager therapeutics for autoimmune diseases. Rallybio shares surged 29.05% to $9.73, reaching a new 52-week high. The transaction is expected to close in mid-2026, with the combined entity operating under the name Candid Therapeutics and trading under ticker 'CDRX'.
Recursion Pharmaceuticals acquired full ownership of REV102, an ENPP1 inhibitor program for treating hypophosphatasia, from Rallybio, reducing pipeline uncertainty and potentially adding value to its drug development efforts.
Rallybio Corporation sold its interest in REV102, a preclinical ENPP1 inhibitor for hypophosphatasia, to Recursion Pharmaceuticals for up to $25 million, extending its cash runway into mid-2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$13.90 per share
Declared
Oct 25, 2026
Ex-dividend
Nov 23, 2026
Pay date
Nov 30, 2026
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.